InflaRx (NASDAQ:IFRX) Announces Earnings Results

InflaRx (NASDAQ:IFRX) posted its earnings results on Monday. The company reported ($0.16) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.16), Zacks reports. The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.03 million.

InflaRx Price Performance

Shares of NASDAQ IFRX traded down $0.09 during mid-day trading on Wednesday, reaching $1.57. The company’s stock had a trading volume of 4,424,450 shares, compared to its average volume of 1,085,727. InflaRx has a 52 week low of $0.71 and a 52 week high of $2.82. The stock has a fifty day moving average of $1.38 and a two-hundred day moving average of $1.18. The firm has a market capitalization of $105.06 million, a PE ratio of -1.97 and a beta of 1.38.

Analyst Upgrades and Downgrades

IFRX has been the topic of a number of research analyst reports. Raymond James Financial restated an “outperform” rating on shares of InflaRx in a research report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of InflaRx in a research note on Wednesday, November 5th. Guggenheim upped their price target on shares of InflaRx from $10.00 to $22.00 and gave the company a “buy” rating in a research report on Monday. HC Wainwright initiated coverage on shares of InflaRx in a report on Tuesday, September 2nd. They issued a “buy” rating and a $6.00 price objective on the stock. Finally, Wall Street Zen lowered shares of InflaRx from a “hold” rating to a “sell” rating in a research report on Saturday. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $8.60.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Cubist Systematic Strategies LLC raised its position in shares of InflaRx by 33.9% during the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock valued at $31,000 after buying an additional 7,616 shares during the last quarter. Adage Capital Partners GP L.L.C. purchased a new position in InflaRx during the second quarter valued at $262,000. Finally, Woodline Partners LP bought a new stake in InflaRx in the 1st quarter valued at $766,000. 42.39% of the stock is currently owned by institutional investors.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.